<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04372706</url>
  </required_header>
  <id_info>
    <org_study_id>RTX-240-01</org_study_id>
    <nct_id>NCT04372706</nct_id>
  </id_info>
  <brief_title>RTX-240 Monotherapy and in Combination With Pembrolizumab</brief_title>
  <official_title>Phase 1/2 Study of RTX-240 Monotherapy and in Combination With Pembrolizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rubius Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rubius Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label, multicenter, multidose, first-in-human Phase 1/2 study of RTX-240 monotherapy or&#xD;
      in combination of pembrolizumab for the treatment of patients with (1) relapsed/refractory&#xD;
      R/R or locally advanced solid tumors (Phase 1/2) or (2) R/R AML (Phase 1 only).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1/2, open label, multicenter, multidose, first-in-human (FIH) dose escalation&#xD;
      and expansion to determine the safety and tolerability, recommended phase 2 dose and optimal&#xD;
      dosing interval, pharmacology, and antitumor activity of RTX-240 in adult patients with&#xD;
      relapsed/refractory or locally advanced solid tumors (Phase 1/2) or relapsed/refractory acute&#xD;
      myeloid leukemia (Phase 1 only) and RTX-240 in combination pembrolizumab in adult patients&#xD;
      with with R/R or locally advanced solid tumors (Phase 1 only). RTX-240 is a cellular therapy&#xD;
      that co-expresses 4-1BBL and IL-15TP, a fusion of IL-15 and IL-15 receptor alpha, with the&#xD;
      goal of harnessing the innate and adaptive immune systems for the treatment of cancer. The&#xD;
      study will include a monotherapy dose escalation phase followed by an expansion phase in&#xD;
      specified tumor types.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 6, 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Assessment: Measured by incidence of Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to 38 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose limiting toxicities (DLTs) of study treatment as determined by incidence and severity of adverse events (AEs)</measure>
    <time_frame>Up to 38 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics (PD) of study treatment will be evaluated through changes in NK cell number relative to baseline</measure>
    <time_frame>Up to 38 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics (PD) of study treatment will be evaluated through changes in T-cell number relative to baseline</measure>
    <time_frame>Up to 38 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK of study treatment as measured by detection of the number of RTX cells positive for both 4-1BBL and IL-15 using flow cytometry.</measure>
    <time_frame>Assessed From the 1st dose of RTX-240 until 30 days after last of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of the Immunogenicity of study treatment Measured by the incidence of antibodies to RTX-240</measure>
    <time_frame>Assessed From the 1st dose of RTX-240 until 30 days after last of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity of study treatment measured by clinical benefit rate (CBR) (% of patients who achieve CR, PR or SD)</measure>
    <time_frame>Up to 38 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity of study treatment measured by duration of response (DoR)</measure>
    <time_frame>Up to 38 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity of study treatment measured by progression free survival (PFS)</measure>
    <time_frame>Up to 38 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity of study treatment measured by overall survival (OS)</measure>
    <time_frame>Up to 38 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity of study treatment measured by time to response (TTR).</measure>
    <time_frame>Up to 38 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity of study treatment measured by time to progression (TTP)</measure>
    <time_frame>Up to 38 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Tumor activity of study treatment Measured by Overall Response Rate (ORR) in Dose Escalation</measure>
    <time_frame>Up to 38 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">234</enrollment>
  <condition>Solid Tumor, AML Adult</condition>
  <arm_group>
    <arm_group_label>Part 1: RTX-240 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1: RTX-240 monotherapy dose escalation in Solid Tumors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: RTX-240 Solid Tumor Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2: RTX-240 administered intravenously on Day 1 of each cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: RTX-240 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1: RTX-240 monotherapy dose escalation in AML</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 4: RTX-240 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1: RTX-240 dose escalation in combination with Pembrolizumab in Solid Tumors</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RTX-240</intervention_name>
    <description>Engineered red cells co-expressing 4-1BBL and IL-15TP</description>
    <arm_group_label>Part 1: RTX-240 Dose Escalation</arm_group_label>
    <arm_group_label>Part 2: RTX-240 Solid Tumor Expansion</arm_group_label>
    <arm_group_label>Part 3: RTX-240 Dose Escalation</arm_group_label>
    <arm_group_label>Part 4: RTX-240 Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Humanized immunoglobulin G4 programmed death receptor¬ 1 blocking</description>
    <arm_group_label>Part 4: RTX-240 Dose Escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent obtained prior to study procedures&#xD;
&#xD;
          -  Patients ≥18 years with an ECOG 0 or 1 (Parts 1, 2 and 4) or 0-2 (Part 3).&#xD;
&#xD;
          -  Relapsed/Refractory (R/R) or locally advanced, unresectable solid tumor for which no&#xD;
             standard therapy exists (Parts 1, 2 and 4), or for which the patient is ineligible or&#xD;
             has declined standard therapy or R/R, cytologically confirmed AML (Part 3).&#xD;
&#xD;
          -  Disease must be measurable per Response Evaluation Criteria&#xD;
&#xD;
          -  The shorter of 28 days or 5 half-lives must have elapsed since the completion of prior&#xD;
             therapy, before initiation of study treatment.&#xD;
&#xD;
          -  Adequate Organ Function and Blood Cell Counts (Parts 1, 2, and 4) as Defined by the&#xD;
             protocol:&#xD;
&#xD;
               -  GFR ≥ 50 mL/min/1.73,&#xD;
&#xD;
               -  AST and ALT ≤ 3 × the ULN and total bilirubin ≤ 1.5 × ULN, in the absence of&#xD;
                  cancer within the liver&#xD;
&#xD;
               -  Or AST and ALT ≤ 5 × ULN and total bilirubin ≤ 3 × ULN, in the setting of primary&#xD;
                  or metastatic liver tumors.&#xD;
&#xD;
               -  ANC ≥ 10 × 103/μL and platelet count ≥ 100 × 103/μL without myeloid growth factor&#xD;
                  support or transfusion, respectively, for at least one week.&#xD;
&#xD;
               -  Hemoglobin should be ≥ 9 g/dL without red blood cell transfusion for at least two&#xD;
                  weeks.&#xD;
&#xD;
               -  Patients must have LVEF ≥ 45%&#xD;
&#xD;
          -  Patients enrolling into Part 2 of the study must be diagnosed with a solid tumor that&#xD;
             has been selected for an expansion cohort&#xD;
&#xD;
               -  Patients must have LVEF ≥ 45%&#xD;
&#xD;
               -  Patients enrolling into Part 4 must have relapsed following or have been&#xD;
                  refractory to a prior PD 1 or PD L1 blocking antibody.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primary central nervous system (CNS) malignancy or CNS involvement, unless&#xD;
             asymptomatic, previously treated, and stable without steroids (Parts 1, 2 and 4) or&#xD;
             known CNS leukemia (Part 3).&#xD;
&#xD;
          -  Known hypersensitivity to any component of study treatment or excipients.&#xD;
&#xD;
          -  Positive antibody screen using institution's standard type and screen test.&#xD;
&#xD;
          -  Clinically significant, active and uncontrolled infection, including human&#xD;
             immunodeficiency virus (HIV), Hepatitis B virus (HBV), or Hepatitis C virus (HCV).&#xD;
&#xD;
          -  Clinically significant coagulopathy, uncontrolled hypertension or autoimmune hemolytic&#xD;
             anemia&#xD;
&#xD;
          -  Leukemic blast count ≥25 x 103/µL (Part 3)&#xD;
&#xD;
          -  Concomitant conditions requiring active immunosuppression&#xD;
&#xD;
          -  Grade 3 immune related Adverse Event (irAE)&#xD;
&#xD;
          -  Prior malignancy within the past 3 years, with protocol specified exceptions&#xD;
&#xD;
          -  History of severe hypersensitivity to a PD 1/PD L1 blocking Ab unless previously&#xD;
             rechallenged successfully (Part 4)&#xD;
&#xD;
          -  Current noninfectious pneumonitis or a history of radiation pneumonitis or pneumonitis&#xD;
             that required steroids or greater immune related pneumonitis, hepatitis, hypophysitis,&#xD;
             or other endocrinopathy (Part 4)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christina Coughlin, M.D., Ph.D.</last_name>
    <phone>617-679-9600</phone>
    <email>chris.coughlin@rubiustx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandip Patel, MD</last_name>
      <phone>585-822-6477</phone>
      <email>patel@ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Angeles Clinic &amp; Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saba Mukarram</last_name>
      <phone>310-231-2181</phone>
      <email>SMukarram@theangelesclinic.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute/ Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Cannon Research Institute</last_name>
      <phone>844-482-4812</phone>
      <email>asksarah@sarahcannon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center/UMHC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Merchan, MD</last_name>
      <phone>305-243-1287</phone>
      <email>Merchan2@med.miami.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Sullivan, MD</last_name>
      <phone>617-724-5197</phone>
      <email>rsullivan7@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Nurse Navigator, RN</last_name>
      <phone>212-342-5162</phone>
      <email>cancerclinicaltrials@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Sciences University - Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Knight Cancer Institute Clinical Trials</last_name>
      <email>trials@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Usama Gergis, MD</last_name>
      <phone>215-955-4367</phone>
      <email>Usama.Gergis@jefferson.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Brodeur</last_name>
      <phone>412-623-2944</phone>
      <email>brodeurs@upmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Cannon Research Site</last_name>
      <phone>615-329-7478</phone>
      <email>CANN.ResearchReferrals@scresearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Spira, MD, PhD,</last_name>
      <phone>703-280-5390</phone>
      <email>alexander.spira@usoncology.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 23, 2020</study_first_submitted>
  <study_first_submitted_qc>April 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2020</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

